argenx FIRST LOOK: Amgen's Phase 3 MG data
Competitor Amgen announced topline results from its Phase 3 MINT study with Uplizna in generalised myasthenia gravis. We note the suggested semi-annual dosing frequency and solid clinical improvements, but still consider Vyvgart to be the top contender in an increasingly crowded space. We reiterate our € 530 TP and Accumulate rating for argenx.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.